Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Company Overview - Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [3] - The company's lead candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus [3] Clinical Programs - Olvi-Vec is currently being evaluated in a Phase 3 registrational trial (OnPrime/GOG-3076) for platinum-resistant/refractory ovarian cancer, comparing its efficacy and safety in combination with platinum-doublet + bevacizumab against physician's choice of chemotherapy and bevacizumab [3] - The company is also conducting a Phase 1b/2 trial in small-cell lung cancer (SCLC) and a Phase 2 trial in non-small cell lung cancer (NSCLC) [2] Upcoming Events - Thomas Zindrick, President, CEO, and Chairman of the Board, will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024 [1] - The session will be moderated by Emily Bodnar, a biotech equity research analyst, and will begin at 11:00 a.m. ET [2]